Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfenex partners Lucentis biosimilar with Hospira; terminated

Executive Summary

On the heels of its $17bn acquisition by Pfizer Inc., Hospira Inc. licensed exclusive global rights to develop, manufacture, and sell Pfenex Inc.'s Phase Ib/IIa PF582, a biosimilar of Genentech Inc.'s Lucentis (ranibizumab) for wet AMD. Hospira and Pfenex may also collaborate on other products in the future, including co-development on other ophthalmic biologic VEGF-A inhibitors.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies